TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06649344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 Injection
Description: HRS9531 injected subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 Injection
Description: HRS9531 injected subcutaneously once weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Injection
Description: Semaglutide injected subcutaneously once weekly.
Study: NCT06541041

Intervention type: DEVICE
Intervention: Brief intraoperative electrical stimulation
Description: Intraoperative brief electrical stimulation (BES) will be performed using a handheld nerve stimulator (Checkpoint Guardian) to stimulate the donor nerves at 2 mA with a 200 µs pulse duration for 10 minutes per nerve.

Intervention type: DEVICE
Intervention: Temporary Postoperative Peripheral Nerve Stimulation
Description: An implantable temporary peripheral nerve stimulator (SPRINT PNS System) will be placed during the surgery with one lead for each donor nerve. The implantable peripheral nerve stimulator will be programmed to optimize postoperative pain control on an individualized basis. The peripheral nerve stimulator will be explanted after 60 days, as is intended for this device.
Study: NCT05874791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management training
Description: metacognitive group intervention
Study: NCT04850287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Sensors for Population Awareness about Health Issues using Social Media
Description: A clustered randomized control trial will be conducted and ZIP Codes from each demographic environment will be randomly assigned to control and intervention arms. Digital educational materials about organ donation will be exposed to online users in social media belonging to ZIP Codes assigned to the intervention arm

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Sensors for Population Awareness about Health Issues using Social Media
Description: A clustered randomized control trial will be conducted and ZIP Codes from each demographic environment will be randomly assigned to control and intervention arms. Digital educational materials about organ donation will be exposed to online users in social media belonging to ZIP Codes assigned to the intervention arm
Study: NCT06167655

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostimulator
Description: Neurostimulation system that applies stimulation to nerve pathways in the head associated with migraine symptoms.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurostimulator
Description: Neurostimulation system that applies stimulation to nerve pathways in the head associated with migraine symptoms.
Study: NCT06658600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician readers will be assisted with AI-derived probability and diagnosis of obstructive coronary heart disease
Description: Physician readers will be assisted with AI-derived probability and diagnosis of obstructive coronary heart disease. The AI tool provides individualized obstructive CHD probabilities and diagnosis, leveraging retinal biomarkers associated with cardiovascular risk.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician readers will be assisted with RF-CL table to calculate the probability of obstructive coronary heart disease
Description: Physicians use a RF-CL table (risk factor weighted clinical likelihood table) to calculate the probability of obstructive CHD.
Study: NCT04776434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)
Description: This study will capture data from the use of the SELUTION SLR according to its approved labelling.
Study: NCT06614205

Intervention type: DIAGNOSTIC_TEST
Intervention: tumoral dosimetry by scintigraphy
Description: The tumoral dosimetry has been done on patient after treatment by 177Lu-DOTATATE Theses patients performed a scintigraphy exam at D1, D4 and D7 after the treatment
Study: NCT06615674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia
Description: The first group is the Dapagliflozin group, which will get Dapagliflozin 10mg once a day every morning for 14 days. And the second group will have placebo for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia
Description: The first group is the Dapagliflozin group, which will get Dapagliflozin 10mg once a day every morning for 14 days. And the second group will have placebo for 14 days.
Study: NCT06613646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection of the subacromial bursa and pectoralis minor
Description: Patients will first receive an ultrasound-guided injection of the subacromial bursa. After the subacromial bursa injection, patients will be monitored for 1 hour, after which the level of relief in their complaints will be assessed using the Numeric Rating Scale (NRS), and passive range of motion will be measured.~Following the subacromial bursa injection, patients will receive an ultrasound-guided injection of the pectoralis minor muscle. After the pectoralis minor muscle injection, patients will again be monitored for 1 hour, after which the level of relief in their complaints will be assessed using the NRS, and passive range of motion will be measured.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine (drug)
Description: 5 mL of 2% lidocaine will be used as a local anesthetic for the subacromial bursa injection, and 4 mL of 2% lidocaine will be used for the pectoralis minor muscle injection.
Study: NCT06401993

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The dao qi tong luo group
Description: The dao qi tong luo group will accept acpuncture. Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu) and etc. Among them, the dao qi tong luo group will make patients feel qi.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: The acupuncture group
Description: The acupuncture group will accept acpuncture. Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu) and etc. The acupuncture group will not feel qi.
Study: NCT06614426

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group 1 (T1)
Description: Test group 1 (T1): Open flap debridement using electrolysis decontamination

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group 2 (T2)
Description: Test group 2 (T2): Open flap debridement using electrolysis decontamination combined with L-PRF application
Study: NCT05342402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Somatosensory Rehabilitation Program
Description: Somatosensory rehabilitation program includes minimizing contact with the painful zone of the vulva and uses tactile stimulation at a tolerated distance from the vulva. Each participant will also receive advice on resuming sexual activities with vaginal penetration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Pain Management Program
Description: Educational Pain Management Program includes education on decreasing irritative contacts with the vulva and relaxation techniques. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
Study: NCT06614426

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group (C)
Description: Conventional open flap debridement
Study: NCT06614946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Safety Plan (ESP)
Description: Participants will receive an electronic safety plan in the ED. ESP focuses on developing a personalized coping plan to manage suicidal thoughts and urges.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Safety Plan (ESP)
Description: Participants will receive an electronic safety plan in the ED. ESP focuses on developing a personalized coping plan to manage suicidal thoughts and urges.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text support
Description: Those in the text-based support program will receive up to 2 texts per day for a month with varying levels of tailoring, based on ESP and dynamic personalized feedback.
Study: NCT05438732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smaller incision, new generation implantable miniature telescope (SING-IMT)
Description: The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
Study: NCT06478654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Modified Pectoral Nerve Block (PECS II).
Description: The procedure will be done bilateral with the patient lying in the supine position and the ipsilateral arm will be abducted and externally rotated, and the elbow flexed 90°.~The block will be managed by in-plane technique. After confirming the location of the needle with 2-3 mL of saline, 10 mL of 0.25% bupivacaine will be injected. Then, the needle will be advanced to the interfascial plane between the pectoralis minor and serratus anterior muscle, and 20 mL of 0.25% bupivacaine will be administered with the same procedure. The Block will be repeated on the other side using similar technique taking into consideration the toxic dose of bupivacaine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Thoracic Erector spinae plane block (ESPB).
Description: Under all aseptic precautions and sonar guided, ESP block will be managed at T4 or T5 bilateral using a high-frequency linear ultrasound probeWe will inject 20ml of bupivacaine 0.25% into interfacial plane below to erector spinae, a manifest linear pattern will be visualized uplifting the muscle. The Block will be repeated on the other side using similar technique taking into consideration the toxic dose of bupivacaine.
Study: NCT05196633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radial extracorporeal shock wave therapy
Description: rESWT (Endopuls 811; Enraf Nonius B.V. Va-reseweg 127, 3047 AT Rotterdam MedTech, Wessling, Germany) will be applied on the myotendinous junction of both the gastrocnemius and the soleus muscles in post-stroke spasticity patients. 2000 shots will be applied on the gastrocnemius and soleus myotendinous junction with a frequency of 10 Hz and energy density of 60 mJ (1 bar) within tolerable pain limits.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham radial extracorporeal shock wave therapy
Description: The control group will receive sound over the myotendinous junction of gastrocnemius and soleus with transducer-like contact.
Study: NCT04680910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Targeted propofol infusion in TRD patients will induce sedation with maximal expression of EEG slow waves and minimal burst suppression.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: EEG will be recorded during propofol infusion and during overnight sleep. Sleep EEG data will be acquired for a minimum of one night prior to the first sedation session, providing a baseline measure. Additional overnight sleep recordings will be performed on day of sedation and subsequent nights.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Slow-Wave Activity
Description: Duration of slow waves during sedation will be evaluated using automated approaches. SWA during sedation will be calculated as the total power in the 0.5-4 Hz frequency band/total time in minutes. SWA during N2/N3 sleep will be calculated as the total power in the 0.5-4 Hz frequency band/total time in minutes in the N2 and N3 sleep stages. Delta sleep ratio will be computed from the SWA measured during the first and second N2/N3 cycles.
Study: NCT06063850

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV9-hSyn1-miGRIK2
Description: AMT-260 is an AAV9 gene therapy product that locally delivers miRNA silencing technology to target the GRIK2 gene and suppress aberrantly expressed GluK2 containing kainate receptors. Intervention will be a one-time intracerebral administration of AMT-260.
Study: NCT05833360

Intervention type: DEVICE
Intervention: Exai oncRNA blood test
Description: A phlebotomist will collect approximately 40 ml (about 2-3 tablespoons) of blood from the subjects after consent. The Exai oncRNA blood test will be run on the blood samples.

Intervention type: DEVICE
Intervention: Exai oncRNA blood test
Description: A phlebotomist will collect approximately 40 ml (about 2-3 tablespoons) of blood from the subjects after consent. The Exai oncRNA blood test will be run on the blood samples.

Intervention type: DEVICE
Intervention: Exai oncRNA blood test
Description: A phlebotomist will collect approximately 40 ml (about 2-3 tablespoons) of blood from the subjects after consent. The Exai oncRNA blood test will be run on the blood samples.

Intervention type: DEVICE
Intervention: Exai oncRNA blood test
Description: A phlebotomist will collect approximately 40 ml (about 2-3 tablespoons) of blood from the subjects after consent. The Exai oncRNA blood test will be run on the blood samples.
Study: NCT06423196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: In the development of the exercises, the players will mobilise dumbbells of different weights that will be estimated according to the calculation of 30% of 1 RM. This workload with dumbbells is based on previous work where blood flow restriction was used in healthy athletes.
Study: NCT06287450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RSV Vaccine (IN006)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RSV Vaccine (IN006)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RSV Vaccine (IN006)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RSV Vaccine (IN006)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RSV Vaccine (IN006)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RSV Vaccine (IN006)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RSV Vaccine (IN006)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT05841836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Suture-Mediated Closure System
Description: To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perclose ProGlide Suture-Mediated Closure System
Description: To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
Study: NCT05392517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-mobilization technique along with conventional therapy
Description: Group A will be treated with self-mobilization technique of thoracic spine with the frequency of 2 sets of 10 repetitions thrice per week for a total of six weeks and conventional treatment.~Self-mobilization technique will be comprised of self-mobilization technique using tennis balls and foam roller. The participant will be supine with knees in 90-degree flexion.~* Mobilization Technique 1: Cross your arms over your chest so that you are in slight flexion and then slowly begin to move your shoulders and head closer to the floor placing the mid back into extension over the balls joined to make mobilization device. Hold this position for 3 seconds and then return to the flexed position.~* Mobilization Technique 2: Lying lengthwise on the foam roller, clasp your hands together in front of you, above your chest with arms straight. Slowly move your arms above your head until you feel a good stretch. This exercise should be pain free. Hold stretch for 30- 60 seconds.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional therapy
Description: Group B will be treated with the conventional treatment (heating pad, ultrasound, thoracic strengthening exercises
Study: NCT04997720

Intervention type: OTHER
Group type: OTHER
Intervention: Training
Description: Each course will consist of:~1. Initial evaluation~2. Theoretical tutorial~3. Training with exercises of increasing complexity.~4. Final evaluation.
Study: NCT05726370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immunoglobulin G4 monoclonal antibody, via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CISPLATIN
Description: Platinum agent, via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Platinum agent, via IV infusion
Study: NCT05560451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer health coach intervention
Description: Eligible participants will be randomly assigned to receive a telehealth delivered peer health coach intervention to promote health outcomes and behavior change among Veterans with multimorbidty.
Study: NCT05726370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Antineoplastic agent, via IV infusion.
Study: NCT05901207

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: blood test
Study: NCT06363981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS over the left DLPFC and over the left DMPFC
Description: Active rTMS over the left DLPFC and over the left DMPFC to induce the long term potentiation of stimulated areas.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS over the left DLPFC
Description: Active rTMS over the left DLPFC to induce the long term potentiation of stimulated area.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS over the left DLPFC or over the left DLPFC and over the left DMPFC for placebo.
Study: NCT05363930

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel motorized spiral enteroscopy
Description: Novel motorized spiral enteroscopy (Olympus Medical Systems Corporation, Tokyo, Japan) procedures would be performed under general anaesthesia with nasotracheal intubation under fluoroscopic guidance. Four litres of PEG was given to all patients with at least 8 hours of fasting prior to NMSE. Initially antegrade enteroscopy would be performed failing which retrograde enteroscopy would be done to reach the lesion. If the desired lesion is not reached via antegrade/retrograde route, hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anesthesia using the same overtube. The time of procedure will be calculated from insertion of NMSE to its withdrawal. The depth of insertion would be measured by sequential withdrawal technique.
Study: NCT05050630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR2-ICE
Description: Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.
Study: NCT05363930

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single balloon enteroscopy
Description: Single balloon enteroscopy will be performed with single balloon video-enteroscope (Olympus Medical Systems, Tokyo, Japan) under monitored anaesthesia (deep sedation with propofol). Initially antegrade/retrograde enteroscopy would be performed based on pre-procedure localization failing which enteroscopy would be done from opposite route to reach the lesion. Hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anaesthesia using the same overtube. Duration of procedure would be calculated from the time of introduction of the enteroscope to time of removal. The depth of insertion would be measured using the push and pull technique.
Study: NCT05110183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: A cochlear implant electrode will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software on a laptop computer will be used to control the delivery of a sequence of charge balanced current pules.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: optical stimulation
Description: Optical fibers will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software will be used to control the delivery of a sequence of charge balanced current pules.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined optical and electrical stimulation
Description: A short hybrid array consisting of optical sources and electrical contacts will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Biphasic electrical current pulse and optical pulse delivery will be controlled in amplitude and timing by a computer.
Study: NCT05522335

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BBV154(Intranasal) & covaxin
Description: Intervention Covaxin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BBV154(Intranasal) & covaxin
Description: Intervention Covaxin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BBV154(Intranasal) & covaxin
Description: Intervention Covaxin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BBV154(Intranasal) & covaxin
Description: Intervention Covaxin
Study: NCT04627701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omega
Description: Omega Implantation
Study: NCT05059587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01
Description: MBA-P01 will be injected into the Glabellar line.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX
Description: Botox will be injected into the Glabellar line.